Nobuhiro Shibata MD, PhD (@shibanob) header
Nobuhiro Shibata MD, PhD (@shibanob) profile picture

Medical Oncologist/Breast Cancer & Supportive Care/Kansai Medical University Hospital /日本臨床腫瘍学会 がん薬物療法専門医・指導医/フルマラソンPB 3時間24分50秒(2019延岡西日本)/発言は所属を代表するものではありません

Joined August 2021
Photo by Nobuhiro Shibata MD, PhD (@shibanob)Photo by Nobuhiro Shibata MD, PhD (@shibanob)Photo by Nobuhiro Shibata MD, PhD (@shibanob)Photo by Nobuhiro Shibata MD, PhD (@shibanob)Photo by Nobuhiro Shibata MD, PhD (@shibanob)Photo by Nobuhiro Shibata MD, PhD (@shibanob)Photo by Nobuhiro Shibata MD, PhD (@shibanob)
#ESMO26 LBA31 PRABITAS Phase 3 Trial A pragmatic phase 3 non-inferiority trial comparing biweekly vs conventional FTD/TPI + bevacizumab in refractory mCRC. Efficacy:
• OS: 11.3 vs 10.3 mo (HR 0.93, 95% CI 0.80–1.08)
• PFS: 3.9 vs 3.9 mo (HR 0.93, 95% CI 0.81–1.06) Safety:
• Grade ≥3 neutropenia: 13% vs 39%
• Febrile neutropenia: 1% vs 5%
 Biweekly FTD/TPI + bevacizumab demonstrated non-inferior OS with reduced toxicity compared with the conventional schedule. Our institution, Kansai Medical University Hospital, participated in this study. I am pleased to have contributed as a co-author. Simultaneously published in The Lancet! doi.org/10.1016/S0140-6736(2… #PRABITAS #mCRC #ColorectalCancer
@OncoAlert
1
5
318
Nobuhiro Shibata MD, PhD retweeted
Great discussion by Fumikata Hara @9p2nNkRpjOrdvcw. Benefit of ribo comparable to abema. Can we identify who really benefits? Sadly not yet. Best we can do is estimate risk of recurrence and utilize shared decision making based on risks, benefits and patient preferences. #ESMO26
2
14
34
2,236
📢 @ExaWizards has released a press announcement on our TRACK-BC study presented at #ASCO26. ⌚ TRACK-BC is a prospective study investigating changes in patients' daily activity during neoadjuvant chemotherapy using wearable devices and AI. 🤝 I would like to thank @u1rokikawa, all co-investigators, and the patients who participated in this research. 🔗 exawizards.com/en/archives/3… #BreastCancer #DigitalBiomarker #Wearables #ePRO
3
385
📢 @ExaWizards ASCO2026で発表したTRACK-BC研究のプレスリリースが公開されました。 ⌚ウェアラブルデバイスとAIを活用し、術前化学療法中の患者さんの日常生活の変化を評価した前向き研究です。 🤝@u1rokikawa先生をはじめ、共同研究者の皆様、ご協力いただいた患者さんに心より感謝申し上げます。 🔗 exawizards.com/archives/3238… #ASCO26 #BreastCancer #DigitalBiomarker #Wearables #ePRO
📢 @ExaWizards has released a press announcement featuring our TRACK-BC study presented at #ASCO26. ⌚ This prospective study evaluated changes in daily activity during neoadjuvant chemotherapy using wearable devices and AI. 🤝 My sincere thanks to @u1rokikawa, all collaborators, and especially the patients who participated in this study. 🔗 exawizards.com/en/archives/3… #BreastCancer #DigitalBiomarker #Wearables #ePRO
There's a new version of this post
1
160
Nobuhiro Shibata MD, PhD retweeted
Real-World Data on Atezolizumab + Nab-Paclitaxel for PD-L1+ Metastatic TNBC - Tatsunori Shimoi (@shimoi_oncology) @NaokiNiikura @shibanob @u1rokikawa @YukinoriOzaki oncodaily.com/voices/tatsuno…
4
15
526
JBCRG-C08/ATTRIBUTEの結果が npj Breast Cancer に掲載されました。共著者として本研究に参加できたことを大変光栄に思います。 下井先生(@shimoi_oncology)をはじめ、共同研究者の先生方、CRC・研究スタッフの皆様、そして本研究にご参加いただいた患者さんに心より感謝申し上げます。 nature.com/articles/s41523-0… #BreastCancer #TNBC #JBCRG #npjBreastCancer
npjBreastCancer誌にJBCRG-C08/ATTRIBUTEを報告しました。 PD-L1陽性mTNBCに対するatezolizumab+nab-PTXの日本実臨床前向き観察研究です。 79施設151例を登録。irAE 30.9%、SAE 16.8%、mPFS 5.6か月、mOS 22.5か月。 新たな安全性懸念は認めませんでしたが、自己免疫疾患併存例ではirAEが多く、慎重なモニタリングが重要です。 nature.com/articles/s41523-0… @NaokiNiikura @shibanob @u1rokikawa @YukinoriOzaki
1
1
314
Honored to have contributed as a co-author to the JBCRG-C08/ATTRIBUTE study, now published in npj Breast Cancer. My sincere thanks to Dr. Tatsunori Shimoi (@shimoi_oncology), all co-investigators, research staff, and especially the patients who made this study possible. nature.com/articles/s41523-0… #BreastCancer #TNBC #JBCRG #npjBreastCancer
We report JBCRG-C08/ATTRIBUTE in npjBreastCancer, a prospective real-world study of atezolizumab + nab-paclitaxel for PD-L1+ metastatic TNBC in Japan. 151 pts from 79 sites were enrolled. irAEs: 30.9%, SAEs: 16.8%, median PFS: 5.6 mo, median OS: 22.5 mo. No new safety signals were observed, but patients with autoimmune disease require careful monitoring. nature.com/articles/s41523-0… @NaokiNiikura @shibanob @u1rokikawa @YukinoriOzaki
1
5
570